|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: HIV/ HBV Co-infection - More Potency, More Policy
Datamonitor, Sep 2004, Pages: 89
Introduction
Long-term usage of HAART for the management of HIV has reduced mortality in the HIV-infected population. However, this has consequently led to an increase in the prevalence of chronic co-infections such as Hepatitis B (HBV). Currently, HBV prevalence exceeds that of HIV and is estimated at 2 billion infected individuals worldwide, accounting for approximately 5% of the world’s population.
Scope
Key data and epidemiology of the seven major HIV therapeutic markets highlighting the HIV / HBV co-morbid population
Overview of the limitations surrounding co-morbid management such as recognition of co infection, high-risk groups and lack of efficacious antivirals
Report Highlights
Concurrent early diagnosis of both HIV and HBV disease states is pivotal to increasing the lifespan of this co-morbid population. Effective treatment is currently hampered by poor patient compliance, HAART hepatotoxicity and lack of comprehensive treatment guidelines.
Reasons to Purchase
Effectively target this niche sector, through a complete understanding of the prevalence of the co-morbid population in the seven major markets
Identify the most promising products in the HIV and HBV pipelines, and track how current players are seeking to optimize their market share
Scope
Analysis based on interviews with key opinion leaders in the major markets
Report Highlights
Lack of potency with current HBV therapeutics is an obvious gap in treating both mono and co-infected patients currently being addressed by companies such as Gilead and Idenix/Novartis.
Commercial support for global implementation of HBV vaccination need not preclude a high volume/low cost business model for a new potent HBV antiviral.
Customers who bought this item also bought
Commercial and Pipeline Insight: Hepatitis B
Stakeholder Insight: HIV Therapy Dynamics
Pipeline Insight: HIV - The Age of Convenience
The Medical Management of HIV/AIDS
Stakeholder Opinions: HIV/HCV Co-infection - Whose Niche?
Pipeline Insight: HIV - Novel NNRTIs address crucial unmet need
HIV - A Way Of Life
HIV/AIDS Testing - Global Strategic Business Report
Global HIV Market: An Analysis
Commercial Insight: HIV - Reshaping Treatment Paradigms
Stakeholder Opinions: HIV - Reaching the 'Untapped' Patient Population
HIV Update 2002 (2) - February
|
|
|
|
